Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation

Atrial Fibrillation Clinical Trial

Official title:

Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00599118
• Other study ID #: 8271
• Status: Active, not recruiting
• Start date: August 2005
• Est. completion date: December 2035

Study information

• Verified date: August 2023
• Source: The Cleveland Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to establish a genebank repository of blood samples and data to generate information about the hereditary (genetic) basis of atrial fibrillation.

Description:

Blood samples and data will be collected from subjects with atrial fibrillation and normal controls. The primary aim of future research using these samples is to identify mechanisms and pathogenesis of atrial fibrillation. Through this information, we hope to identify targets for new therapies and improve knowledge and understanding of atrial fibrillation. Identification of disease genes could improve strategies that prevent progression of atrial fibrillation to more persistent disease.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1300
• Est. completion date: December 2035
• Est. primary completion date: December 2035
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria for Atrial Fibrillation group:

• Male or female at least 18 years old

• Subjects with a history of or current Atrial Fibrillation

• Subjects able to give informed consent Exclusion Criteria for Atrial Fibrillation group: no history of atrial fibrillation

Inclusion Criteria for Controls:

• Male or female at least 18 years old

• Subjects with no history of Atrial Fibrillation

• Subjects able to give informed consent Exclusion Criteria for controls: History of atrial fibrillation

Related Conditions & MeSH terms

• Atrial Fibrillation

Locations

Country	Name	City	State
United States	Cleveland Clinical Foundation	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
The Cleveland Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Genetic variants associated with atrial fibrillation	Genome-wide association study of atrial fibrillation	Baseline